Grundium, a Tampere-based startup specialising in digital pathology imaging technology, backed by US-based healthcare private equity firm EW Healthcare Partners, has acquired Visiopharm, a Denmark-based provider of AI-driven precision pathology software.
The combined business merges complementary capabilities from Grundium’s imaging platform and Visiopharm’s AI-driven precision pathology software, creating an accessible end-to-end solution for diagnostic laboratories, biopharmaceutical development, and research.
“Precision medicine begins with precision pathology. By combining Grundium’s imaging technologies with Visiopharm’s advanced AI applications, we are creating a stronger foundation for physicians and laboratories to adopt high-value workflows and scale them over time. Together, we can help make precision pathology more accessible, practical, and impactful for customers worldwide,” said Mika Kuisma, CEO of Grundium.
Founded in 2015 by former Nokia engineers, Kimmo Alanen, Mika Kuisma, and Janne Haavisto, Grundium develops compact, high-quality digital pathology scanners for healthcare, education, and research environments.
The company develops the Ocus® series of microscope scanners. Grundium states that these compact, high-precision devices make high-quality digital and remote pathology accessible to all, offering ease of use and affordability for labs of any size.
Founded in 2002 by Michael Grunkin and Johan Doré Hansen, Visiopharm is on a mission to advance precision medicine by transforming pathology through image analysis. It provides an AI-driven precision pathology software for research and diagnostics. In research, it claims to provide tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research.
In diagnostics, it specialises in clinical applications and has nine diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Visiopharm operates internationally with over 750 customer accounts in more than 40 countries.
“Grundium and Visiopharm bring together highly complementary capabilities. This combination allows us to connect biomarker analysis, imaging, and quality management in new ways, while continuing to support the software and workflows our customers rely on today. Together, we are better positioned to support the next phase of precision diagnostics,” said Michael Grunkin, CEO of Visiopharm
The combined platform enables more efficient, scalable digital pathology, while expanding access through compact scanning solutions that lower costs and remove infrastructure barriers.
By combining Grundium’s scanner portfolio with Visiopharm’s AI-driven software, the platform notes that it supports a broad range of use cases, from individual laboratory workflows to enterprise-scale deployments, biomarker development, translational research, clinical studies, and companion diagnostic programmes.
Both companies have previously collaborated by integrating their solutions for laboratories, and the acquisition strengthens this already established partnership.
“Digital pathology has the potential to drastically improve diagnostic accuracy, workflow efficiency and global access to expert care. The platform we are creating brings these capabilities together to make diagnosis faster, more reliable and more efficient, transforming patient care and supporting the development of new breakthrough treatments, particularly in oncology,” said Andy Thomson, Operating Partner at EW Healthcare Partners and Chair of the Board of Grundium.
To maintain continuity for existing customers and partners, Grundium’s digital scanners and Visiopharm’s precision pathology software will continue to be supported and available independently, enabling customers to continue with their current solutions or to combine capabilities as their needs evolve.
Read the orginal article: https://www.eu-startups.com/2026/05/finlands-grundium-acquires-denmarks-visiopharm-to-build-an-end-to-end-ai-precision-pathology-platform/
